KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $2.4 billion.

  • Royalty Pharma's Retained Earnings fell 1719.59% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year decrease of 1719.59%. This contributed to the annual value of $2.4 billion for FY2025, which is 1719.59% down from last year.
  • Royalty Pharma's Retained Earnings amounted to $2.4 billion in Q4 2025, which was down 1719.59% from $2.3 billion recorded in Q3 2025.
  • Royalty Pharma's 5-year Retained Earnings high stood at $2.8 billion for Q4 2024, and its period low was $1.9 billion during Q1 2021.
  • Its 5-year average for Retained Earnings is $2.3 billion, with a median of $2.3 billion in 2021.
  • In the last 5 years, Royalty Pharma's Retained Earnings skyrocketed by 4585.51% in 2021 and then crashed by 1719.59% in 2025.
  • Over the past 5 years, Royalty Pharma's Retained Earnings (Quarter) stood at $2.3 billion in 2021, then dropped by 12.88% to $2.0 billion in 2022, then increased by 28.14% to $2.5 billion in 2023, then increased by 13.03% to $2.8 billion in 2024, then fell by 17.2% to $2.4 billion in 2025.
  • Its Retained Earnings was $2.4 billion in Q4 2025, compared to $2.3 billion in Q3 2025 and $2.2 billion in Q2 2025.